Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: A phase II trial

Growth Factor ◽

Epidermal Growth Factor ◽

Phase Ii ◽

Phase Ii Trial ◽

Growth Factor Receptor ◽

Malignant Astrocytomas ◽

Epidermal Growth ◽

Iodine 125

Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303)

Frontiers in Oncology ◽

10.3389/fonc.2019.00132 ◽

2019 ◽

Vol 9 ◽

Cited By ~ 10

Author(s):

Karen L. Reckamp ◽

Paul H. Frankel ◽

Nora Ruel ◽

Philip C. Mack ◽

Barbara J. Gitlitz ◽

...

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Phase Ii ◽

Kinase Inhibitor ◽

Phase Ii Trial ◽

Growth Factor Receptor ◽

Tyrosine Kinase Inhibitor Therapy ◽

Epidermal Growth ◽

Egfr Mutant

A multicenter phase II trial of gefitinib 500 mg/day in 193 patients with advanced epidermal growth factor receptor-positive solid tumors who had failed previous chemotherapy: Interim data

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.3162 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 3162-3162 ◽

Cited By ~ 3

Author(s):

I. B. Vergote ◽

Y. Humblet ◽

E. van Cutsem ◽

S. van Belle ◽

J. Kerger ◽

...

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Solid Tumors ◽

Phase Ii ◽

Phase Ii Trial ◽

Growth Factor Receptor ◽

Multicenter Phase ◽

Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: A randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie

European Journal of Cancer ◽

10.1016/j.ejca.2015.01.059 ◽

2015 ◽

Vol 51 (5) ◽

pp. 569-576 ◽

Cited By ~ 35

Author(s):

Sylvie Lorenzen ◽

Jorge Riera Knorrenschild ◽

Georg-Martin Haag ◽

Michael Pohl ◽

Peter Thuss-Patience ◽

...

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Phase Ii ◽

Oesophageal Cancer ◽

Phase Ii Trial ◽

Growth Factor Receptor ◽

Line Treatment ◽

Second Line ◽

1462 POSTER A multicenter phase II trial of gefitinib 500 mg/day in 192 patients with advanced epidermal growth factor receptor-positive solid tumors who had failed previous chemotherapy

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(05)81753-7 ◽

2005 ◽

Vol 3 (2) ◽

pp. 423

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Solid Tumors ◽

Phase Ii ◽

Phase Ii Trial ◽

Growth Factor Receptor ◽

Multicenter Phase ◽

3078 Updated results and efficacy analysis according to epidermal growth factor receptor (EGFR) mutation subtypes and metastatic sites for the phase II trial of gefitinib in combination with carboplatin plus S1

European Journal of Cancer ◽

10.1016/s0959-8049(16)31719-1 ◽

2015 ◽

Vol 51 ◽

pp. S623

Author(s):

A. Tamiya ◽

M. Tamiya ◽

T. Shiroyama ◽

T. Tsuji ◽

N. Morishita ◽

...

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Phase Ii ◽

Egfr Mutation ◽

Phase Ii Trial ◽

Growth Factor Receptor ◽

Efficacy Analysis ◽

Epidermal Growth ◽

Metastatic Sites

Phase II trial of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of anaplastic astrocytoma

Journal of Radiation Oncology ◽

10.1007/s13566-012-0071-6 ◽

2012 ◽

Vol 2 (1) ◽

pp. 7-13 ◽

Cited By ~ 1

Author(s):

Ji H. Kim ◽

Linna Li ◽

Tony S. Quang ◽

Jacqueline G. Emrich ◽

Theodore E. Yaeger ◽

...

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Phase Ii ◽

Anaplastic Astrocytoma ◽

Phase Ii Trial ◽

Growth Factor Receptor ◽

TBCRC 022: Phase II trial of neratinib for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer and brain metastases (BCBM).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.528 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 528-528 ◽

Cited By ~ 4

Author(s):

Rachel A. Freedman ◽

Rebecca Sue Gelman ◽

Jeffrey Scott Wefel ◽

Ian E. Krop ◽

Michelle E. Melisko ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Brain Metastases ◽

Phase Ii ◽

Phase Ii Trial ◽

Growth Factor Receptor ◽

Her2 Breast Cancer ◽

Faculty Opinions recommendation of Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.732916089.793560787 ◽

2019 ◽

Author(s):

Steve Plaxe

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Phase Ii ◽

Phase Ii Trial ◽

Growth Factor Receptor ◽

Human Epidermal Growth Factor ◽

Randomized Phase Ii ◽

ABX-EGF, a fully human anti-epidermal growth factor receptor (EGFr) monoclonal antibody: phase II clinical trial in renal cell cancer (RCC)

European Journal of Cancer ◽

10.1016/s0959-8049(02)80828-0 ◽

2002 ◽

Vol 38 ◽

pp. S57 ◽

Cited By ~ 2

Keyword(s):

Clinical Trial ◽

Monoclonal Antibody ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Phase Ii ◽

Renal Cell ◽

Cell Cancer ◽

Growth Factor Receptor ◽

Multicenter Phase II Trial of Neoadjuvant Therapy With Trastuzumab, Docetaxel, and Carboplatin for Human Epidermal Growth Factor Receptor-2–overexpressing Stage II or III Breast Cancer: Results of the GETN(A)-1 Trial

Breast Diseases A Year Book Quarterly ◽

10.1016/s1043-321x(08)80060-4 ◽

2008 ◽

Vol 19 (1) ◽

pp. 86-87

Author(s):

S. Glück

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Neoadjuvant Therapy ◽

Phase Ii ◽

Phase Ii Trial ◽

Growth Factor Receptor ◽

Multicenter Phase ◽